June 22, 2020 / 1:14 PM / 20 days ago

BRIEF-Puretech Presents New Data Reinforcing Galectin-9 As A Compelling Therapeutic Target And Biomarker

June 22 (Reuters) - PureTech Health PLC:

* PURETECH PRESENTS NEW DATA REINFORCING GALECTIN-9 AS A COMPELLING THERAPEUTIC TARGET AND BIOMARKER FOR A RANGE OF CANCERS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

* PURETECH HEALTH - FIRST-IN-HUMAN CLINICAL TRIAL FOR LYT-200 EXPECTED TO BEGIN IN H2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below